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Abstract 
Background: Ganoderma lucidum (Lingzhi; LZ) and San-Miao-San (SMS) are Chinese medicines (CMs) used to treat 
inflammatory ailments and numbing syndrome/arthralgia syndrome (Bi Zheng), respectively. Given that the main 
symptoms of systemic lupus erythematosus (SLE) include inflammation of the joints, joint pain, edema and palpita-
tions of the heart because of problems associated with Bi Zheng, it was envisaged that LZ and SMS could be used as 
potential treatments for this autoimmune disease. This study aims to investigate the anti-inflammatory activity of a 
combination formulation containing LZ and SMS (LZ–SMS) in SLE mice.
Methods: Female adult Balb/c mice of 20–24 weeks of age were used as normal mice (n = 10), whereas female MRL/
lpr mice of 12–24 weeks of age were divided into three groups (n = 10 in each group), including mild, moderate and 
severe SLE mice groups. The clinical characteristics of the SLE and Babl/c mice (i.e., body weight, joint thickness, lupus 
flare, proteinuria, leukocyturia and lymphadenopathy) were assessed. The plasma concentrations of anti-nuclear anti-
body (ANA) and anti-double stranded DNA antibody (anti-ds-DNA) were analyzed by an enzyme-linked immunosorb-
ent assay, whereas the concentration of several key cytokines (IFN-γ, TNF-α, IL-6, IL-10, IL-2, IL-27, IL-12P70, IL-17A and 
IL-21) were analyzed by a Luminex multiplex assay. The gene expression profiles for differentiation of the T helper (Th) 
lymphocytes in splenic CD4+ Th cells were assessed by RT-qPCR. Flow cytometry was used to measure the percent-
ages of CD4+CD25+Foxp3+ Treg cells and CD19+CD5+CD1d+IL-10+ regulatory B (Breg) cells (IL-10+ Bregs).
Results: Concentrations of anti-ds-DNA in the plasma samples collected from the LZ–SMS-treated (500 mg/kg/day 
oral administration for 7 days followed with 50 mg/kg/day intraperitoneal administration for 7 days), moderate and 
severe SLE mice decreased significantly compared with the PBS treated mice (P < 0.05). The gene expression levels 
of the induced regulatory T (iTreg) and natural Treg (nTreg) cells were significantly higher than those of the Th17, Th1 
and “conventional Th cells vs. Treg cells” regulated genes following the LZ–SMS treatment (P < 0.05). The percent-
ages of CD4+CD25+Foxp3+ Treg cells collected from the splenic, thymic and peripheral blood cells, as well as the 
percentages of IL-10+ Bregs collected from the splenic and thymic cells increased significantly in the LZ–SMS-treated 
SLE mice (P < 0.05) compared with the untreated PBS group. The ratio of the percentage of CD4+CD25+Foxp3+ Treg 
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Background
Systemic lupus erythematosus (SLE) is a multi-systemic 
chronic autoimmune relapsing disease with a particu-
larly high prevalence in middle-aged women, where it 
often results in damage to multiple organs, including the 
kidneys, skin, heart, blood vessels and central nervous 
system [1]. Although several drugs have been developed 
for this disease, which have led to considerable improve-
ments in overall survival as well as alleviating the symp-
toms of severe organ damage, they are expensive and 
produce unwanted side effects [2–5].
Ganoderma lucidum (Lingzhi; LZ) has been reported 
to exhibit antioxidant, anti-inflammatory and analge-
sic effects with potential therapeutic benefits against a 
wide range of diseases, including hepatitis, hyperten-
sion, arthritis, bronchitis and malignancy [6–13]. LZ 
induced the expansion of both murine and human CD4+ 
T cells into Foxp3+ regulatory T (Treg) cells, which could 
be used to alleviate acute colitis [14]. LZ has also been 
reported to modulate the activity of peripheral mono-
nuclear cells and suppress the production of SLE-related 
pathogenic cytokines, such as tumor necrosis factor-α 
(TNF-α), as well as interleukin (IL)-1β, IL-12 and IL-6 [5, 
15–17].
San-Miao-San (SMS) is a Chinese medicine (CM) con-
taining a 1:1:1 (w:w:w) mixture of three Chinese herbs, 
including Rhizoma atractylodis (Cangzhu), Cortex phel-
lodendri (Huangbai) and Radix achyranthis bidentatae 
(Niuxi) [18]. This material has been used empirically for 
treating numbing syndrome/arthralgia syndrome (Bi 
Zheng), which is a painful obstructive syndrome caused 
by the invasion of exterior pathogenic factors into the 
muscles, tendons, bones and joints of the sufferer [5, 
18]. According to CM, SLE can be generally classified 
into excessive and deficient syndromes and related to Bi 
Zheng, because this syndrome results in joint problems, 
joint pain, edema and palpitations of the heart because 
of its damaging effects [19]. It was therefore envisaged 
that the combination of SMS with Lingzhi could be ben-
eficial for the treatment of SLE. The combined use of LZ 
and SMS (LZ–SMS) for their anti-inflammatory activities 
was once common practice according to CM herbalists 
because this combination of materials exhibits synergis-
tic therapeutic effects [20]. Furthermore, the results of 
several clinical studies showed that a combined standard 
formulation of LZ and SMS was generally safe and well 
tolerated by patients suffering from rheumatoid arthri-
tis (RA) [18, 21]. However, the in vivo anti-inflammatory 
mechanisms of LZ and SMS for the treatment of SLE 
have not yet been investigated.
We previously investigated the intracellular signal 
transduction mechanisms responsible for regulating 
the activation of human eosinophils, epithelial cells and 
fibroblast-like synoviocytes (FLS) during inflammation, 
and studied the pathological roles of cytokines in aller-
gic and autoimmune diseases [22–25]. This study aims to 
investigate the anti-inflammatory activities of this com-
bined formulation of LZ–SMS in SLE mice.
Methods
Materials
The combined LZ–SMS hot water extract formulation 
used in this study contained a lyophilized powder, which 
was prepared according to a previously reported proce-
dure by researchers at the Institute of Chinese Medicine, 
The Chinese University of Hong Kong, China [18]. This 
extract was prepared by combining LZ 35.7 % with SMS, 
which consists of three Chinese herbs, including Cang-
zhu 21.4 %, Huangbai 21.4 % and Niuxi 21.4 %. The prep-
aration was then dissolved in physiological saline, and the 
resulting solution was analyzed by a Limulus amoebocyte 
lysate assay (sensitivity limit 12 pg/mL; Biowhittaker Inc, 
Walkersville, MD, USA), which revealed that it did not 
contain any detectable lipopolysaccharide. The different 
herbs were authenticated in terms of their chemical com-
position by thin layer chromatography against a reference 
herb and several reference chemical markers, according 
to the Chinese Pharmacopoeia 2010 [26].
Mice
Female MRL/MpJ-Faslpr/2  J (MRL/lpr) mice were pur-
chased from the Jackson Laboratory (Bar Harbor, ME, 
cells to the percentage of CD4+CD25– effector T cells collected from the splenic, thymic and peripheral blood cells 
in LZ–SMS-treated moderate and severe SLE mice increased significantly compared with the untreated PBS group 
(P < 0.05). Furthermore, a comparison with the PBS treatment group revealed significant decreases in the concentra-
tions of several inflammatory cytokines, including IL-21, IL-10 and IL-17A (P < 0.05), as well as significant increases in 
the concentrations of IL-2 and IL-12P70 in the LZ–SMS treated SLE mice (P < 0.05).
Conclusion: LZ–SMS treatment led to significant increases in the percentages of CD4+CD25+Foxp3+ Treg and IL-10+ 
Breg cells, together with a reduction in the plasma concentrations of several inflammatory cytokines and the down-
regulated expression of the corresponding cytokine related genes in SLE mice. The clinical characteristics of the LZ–
SMS-treated SLE mice also improved significantly.
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USA) and maintained under specific pathogen-free 
conditions in the Laboratory Animal Services Center 
(LASC), The Chinese University of Hong Kong (CUHK) 
and Cancer Center of Prince of Wales Hospital, Hong 
Kong. Female adult Balb/c mice (LASC, CUHK) of 
20–24 weeks of age were used as normal mice (n = 10). 
Adult female MRL/lpr SLE mice of 12–24  weeks of age 
(n = 30) were kept in a conventional animal facility. All of 
the experiments conducted in the present study involv-
ing live animals were carried out under strict controls 
according to the Animal Experimentation Ethics Com-
mittee Guide for the Care and Use of Laboratory Ani-
mals, as approved by the Animal Experimentation Ethics 
Committee of CUHK (Ethical approval no.: 14-012-MIS) 
(Additional file 1).
Monitoring of disease activity
The urine samples collected from the different groups 
(n = 10) of mice were analyzed for protein and leukocytes 
by URS-5T urine test strips (Healgen Scientific LLC, Hou-
ston, TX, USA). Female MRL/lpr mice of 12–24 weeks of 
age were divided into three groups (n = 10 in each group), 
including mild, moderate and severe SLE mice accord-
ing to the following proteinuria scoring system: score 
0 0–15 mg/dL, score 1 16–29 mg/dL, score 2 30–99 mg/
dL, score 3  100–299  mg/dL, score 4  300–1999  mg/dL, 
and score 5  ≥2000  mg/dL (score 0–1: mild SLE; score 
2–3: moderate SLE and score 4–5: severe SLE) [27].
Biochemical and physiological parameters
The different groups of MRL/lpr and Balb/c mice (both 
groups n  =  5) were used to investigate the nephritic 
effects of the LZ–SMS formulation on the mice follow-
ing the daily oral and intraperitoneal administration of 
this material for 14 days. The oral administration group 
was given 500 mg/kg/day of the LZ–SMS formulation in 
400 μL of phosphate buffered saline (PBS) from day 1 to 
7 (n = 5 for the lupus mice in each SLE group and Balb/c 
mice in the normal group). A 50 mg/kg/day dose of LZ–
SMS was also prepared in 400 μL of PBS because of its 
limited solubility. This dose was intraperitoneally admin-
istered from day 8 to 14 into the lupus mice or normal 
mice (n =  5 in each case) belonging to each group. For 
the intraperitoneal injection of this lower dose of LZ–
SMS, we only injected clear solutions of the LZ–SMS for-
mulation (about 1.25  mg LZ–SMS/mouse daily), which 
were filtered prior to being injected to remove any insol-
uble materials. PBS was given to each mouse on a daily 
basis at a dose of 400 μL/mouse for 14 days according to 
the same protocol as that used for the PBS control (n = 5 
of each group). The body weight of each mouse was 
measured before and after the administration of the LZ–
SMS formulation to provide some indication of possible 
herbal toxicity [28]. Mice were also culled 1 day after the 
administration of the LZ–SMS formulation to investigate 
several immunological parameters, including the plasma 
concentrations of anti-nuclear antibody (ANA), anti-
double stranded DNA antibody (anti-ds-DNA) and sev-
eral cytokines (IL-2, IL-10, IL-27, IL-21, IL-12P70, IFN-γ, 
TNF-α, IL-17A and IL-6) in the whole blood. Clinical 
signs of lupus flare and disease severity were assessed in 
each group (n = 10) of MRL/lpr mice before and after the 
treatment process using the following four-point scale: 
0–3, where 0 is normal, 1 is mild (affected areas including 
the snout and ears), 2 is moderate (affected area <2 cm on 
the snout, ears and intrascapular region) and 3 is severe 
(affected area >2 cm on the snout, ears and intrascapular 
region) [29].
Histopathological assessment
Longitudinal sections of the kidneys, which were cut 
through the papilla, were fixed in 4  % paraformalde-
hyde buffer and embedded in paraffin. The kidney sec-
tions were subsequently cut into 2-μm-thick slices and 
stained with periodic acid-Schiff (PAS) stain. The num-
ber of mesangial cells in the glomeruli was determined 
by counting their nuclei. Microscopy examination (Leica 
Microsystems, Wetzlar, Germany) was used to evaluate 
the area of the glomeruli, with 100 glomeruli being evalu-
ated in each group. The severities of vessel infiltration, 
interstitial nephritis and glomerulonephritis were scored 
using the following macroscopic scoring system: 0, nor-
mal; 1–2, mild; 3, moderate; and 4–5, severe [30].
Quantitative real‑time polymerase chain reaction 
(RT‑qPCR)
Whole transcriptome analysis for the differentiation of 
the T helper (Th) cells was performed using a mouse T 
helper cell differentiation RT2 profiler PCR array (Qiagen 
GmbH, Hilden, Germany). The RNA was extracted from 
splenic CD4+ Th cells by an RNeasy Mini Kit (Qiagen). 
The splenic CD4+ Th cells were purified by a mouse T 
helper cell isolation kit (Miltenyi Biotec, Bergisch Glad-
bach, Germany) with Th cell purity >95 %. The purified 
RNA from 1 × 106 splenic CD4+ Th cells were analyzed 
according to the manufacturer’s instructions for the RT2 
profiler PCR Array kit by a 384-well Applied Biosystems 
7900HT Fast Real-Time PCR System (Applied Biosys-
tems Inc., Foster City, CA, USA). The mRNA expression 
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where expt is the experiment, ctrl is the control, GOI is 
the gene of interest and HKG is the housekeeping gene.
Flow cytometric analyses of the CD4+CD25+Foxp+ 
Treg cells, CD4+CD25− effector T (Teff) cells 
and CD19+CD5+CD1d+IL‑10+ Breg cells
Peripheral blood, splenic and thymic cells (1 × 106 cells 
in each case) from the MRL/lpr and Balb/c mice were 
stained to determine the number of CD4+CD25+Foxp+ 
Treg cells [fluorescein peridinin chlorophyll protein/
PerCP-conjugated CD4+, allophycocyanin/APC-con-
jugated CD25+  (BioLegend, San Diego, CA, USA) and 
Alexa Fluor 488-conjugated Foxp+  (BD Pharmingen 
Corp., San Diego, CA, USA) T lymphocyte sub-pop-
ulations], CD4+CD25– Teff cells and IL-10+  Breg cells 
[(CD19+CD5+CD1d+ regulatory B cell) cocktail and 
Phycoerythrin/Cyanine Dye 7 (PE/Cy7)-conjugated anti-
IL-10 antibody (BioLegend)] by flow cytometry (Beck-
man Navios flow cytometer, Beckman Coulter Inc., Brea, 
CA, USA).
Plasma concentrations of ANA and anti‑ds‑DNA
The plasma ANA and anti-ds-DNA concentrations in 
each group were measured by an enzyme-linked immu-
nosorbent assay (ELISA) with commercial reagent kits 
(Mybiosource, Inc., San Diego, CA, USA).
Plasma cytokine concentrations of MRL/lpr and Balb/c 
mice
Plasma was harvested and stored at –80 °C prior to being 
subjected to a multiplex immunoassay to measure several 
cytokines (i.e., IL-2, IL-10, IL-27, IL-21, IL-12P70, IFN-γ, 
TNF-α, IL-17A and IL-6) using a Milliplex MAP kit assay 
reagent (Merck Millipore, Billerica, MA, USA) with a 
Bio-Plex 200 suspension array system (Bio-Rad Laborato-
ries, Hercules, CA, USA).
Statistical analysis
The results for the statistical analysis of the gene array 
data are described in the gene array hybridization and 
data analysis section. These results have been expressed 
as the mean ± standard deviation (SD) for normally dis-
tributed data. Non-parametric data have been expressed 
as the median values (interquartile range, IQR). Mann–
Whitney U tests were used for the continuous variables. 
A comparison of the different groups was achieved by 
Kruskal–Wallis ANOVA, followed by Dunn’s post-test 
for comparing the differences and calculating a P value 
for each pair of comparison. Two-way ANOVA was used 
to compare the different groups and treatments, followed 
by Bonferroni post-test analysis for comparing the repli-
cate means and calculating a P value for each data pair. 
All hypotheses were two-tailed, and P values less than 
0.05 were considered significant. All of these data were 
analyzed by the 6.0 for Windows version of the GraphPad 
Prism software (GraphPad Software, La Jolla, CA, USA).
Results
SLE disease characteristics of MRL/lpr mice
The clinical characteristics of the different mice are sum-
marized in Table 1. The MRL/lpr mice treated with PBS 
were initially stratified into three subgroups (i.e., mild, 
moderate or severe) based on their disease activity, which 
provided a reflection of their proteinuria scores. The per-
centages of lymphadenopathy and the body weights in 
the different groups of MRL/lpr mice were significantly 
higher than those of the control mice (P =  0.034). Fur-
thermore, no obvious adverse side effects were observed 
in the MRL/lpr mice used in the present study, as evi-
denced by the lack of significant loss of body weight upon 
LZ–SMS administration, all P > 0.05. All of the MRL/lpr 
mice in the moderate (P < 0.001) and severe (P = 0.035) 
groups had significantly higher proteinuria and leukocy-
turia scores than the control mice. However, there were 
no significant differences in these scores between the 
mild and control groups (P = 0.056). The joint thickness 
and lupus flare scores of the MRL/lpr mice in the moder-
ate (P = 0.036) and severe (P = 0.030) groups were sig-
nificantly higher than those of the control group.
Attenuation of nephritis in MRL/lpr mice treated with LZ–
SMS
To confirm the immunoregulatory and therapeutic roles 
of LZ–SMS in  vivo, we measured the nephritis clini-
cal characteristics of the MRL/lpr mice after they had 
been treated with LZ–SMS or PBS. As shown in Fig. 1, 
the proteinuria, leukocyturia, lupus flare, glomerulone-
phritis, interstitial nephritis and vessel infiltrate scores 
for the MRL/lpr mice without LZ–SMS treatment were 
significantly higher than those of the Balb/c control (all 
P  <  0.05). Furthermore, the results for the LZ–SMS-
treated MRL/lpr mice revealed that there were obvious 
remissions in the extent of the nephritic disease com-
pared with PBS treatment alone, especially in the severe 
SLE mice (Figs.  1, 2). Moreover, there were significant 
differences in the plasma concentrations of ANA and 
anti-ds-DNA antibodies in the moderate and severe SLE 
mice compared with the Balb/c control mice treated 
with PBS (all P < 0.01) (Fig. 3). Although the plasma con-
centrations of ANA and anti-ds-DNA antibodies in the 
moderate and severe SLE mice treated with LZ–SMS 
were significantly higher than those of the Balb/c con-
trol mice, the plasma concentrations of anti-ds-DNA in 
the moderate (P < 0.001) and severe SLE mice (P = 0.05) 
were both significantly lower than those of the PBS-
treated mice.
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Gene expression profile of Th cell differentiation
A common logarithm of gene expression revealed 
that the expression levels of Th1 cell-regulated genes 
(Ifng, Il12rb2, Il18r1, Il18rap, Fasl and Tbx21) and 
conventional Th cell vs. Treg cell-regulated genes (Cac-
na1f, Chd7, Foxp3, Gata4, Hopx, Hoxa10, Hoxa3, Id2, 
Ikzf2, Il1r2, Il2ra, Lrrc32, Perp, Pkd2, Tnfrsf9, Trp53inp1, 
Uts2 and Zeb1) were significantly lower than those of the 
Table 1 Clinical characteristics of MRL/lpr and Balb/c mice before treatment
Joint thickness was measured in three joints of each hind paw (tarsus joint); Leukocyturia score was determined by a four-point scale (0–3, where 0 was normal and 3 
was severe); No. (%), percentages of mice had lymphadenopathy among each group
SD standard deviation, MRL/lpr MRL/MpJ-Faslpr/2 J, Mild mice with mild disease activity (mild SLE, proteinuria score is 0–1), Moderate moderate disease activity 
(moderate SLE, proteinuria score is 2–3), Severe high disease activity (severe SLE, proteinuria score is 4–5), Normal age- and sex- matched healthy Balb/c mice
&  P = 0.03, && P = 0.008, &&& P = 0.0008, comparing between control and mild SLE mice
* P = 0.03, ** P = 0.008, *** P = 0.0008, comparing between control and moderate SLE mice
#  P = 0.03, ## P = 0.008, ### P = 0.0008, comparing between control and severe SLE mice
MRL/lpr (n = 30) Balb/c
Mild (n = 10) Moderate (n = 10) Severe (n = 10) Normal (n = 10)
Clinical assessment
Body weight, mean ± SD, g 48.0 ± 8.7& 49.4 ± 9.1** 48.7 ± 4.1# 19.2 ± 0.2
Joint thickness, mean ± SD, μm 84.3 ± 3.1 84.7 ± 2.7* 84.4 ± 2.4 79.3 ± 3.6
Lupus flare score, mean ± SD 0.7 ± 0.5 1.0 ± 0.9 1.3 ± 1.0# 0
Proteinuria score, mean ± SD 1.5 ± 0.5 2.8 ± 0.4*** 4.0 ± 1.1### 0.7 ± 0.6
Leukocyturia score, mean ± SD 0.5 ± 1.2 2.0 ± 1.4* 2.5 ± 0.5## 0
Lymphadenopathy, No. (%) 10/10 (100 %)&&& 10/10 (100 %)*** 10/10 (100 %)### 0/10 (0 %)
Fig. 1 Clinical characteristics of MRL/lpr mice with LZ–SMS or PBS treatment. The results of each score system of signs a proteinuria, b leukocyturia, 
c lupus flare, d glomerulonephritis, e interstitial nephritis and f vessels infiltration are presented as bar charts showing the arithmetic mean plus SD. 
* <0.05, **P < 0.01, ***P < 0.001, PBS- vs. LZ–SMS-treated MRL/lpr mice; &P < 0.05, &&P < 0.01, &&&P < 0.001, Balb/c control mice vs. PBS-treated MRL/
lpr mice; ##P < 0.01, ###P < 0.001, Balb/c control mice vs. LZ–SMS-treated MRL/lpr mice (n = 5 in each group)
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Fig. 2 Effects of LZ–SMS treatment on nephritis disease in severe MRL/lpr mice. Kidney tissues from MRL/lpr mice were collected and fixed in 4 % 
paraformaldehyde. The tissue sections were stained with PAS. Representative kidney histopathology in (a–c) PBS and (d–f) LZ–SMS treated SLE mice 
are shown. a, d PAS staining of a representative renal tubular area is shown (100×). Black arrow depicts the protein cast in tubular area. b, e PAS 
staining of a representative perivascular area is shown (100×). Black arrow depicts the mononuclear cells infiltration on vessel. c, f PAS staining of a 
representative glomerulus area is shown (400×). Bold red arrow depicts the mononuclear cells infiltration round glomerulus (n = 5 in each group)
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Th2 cell-regulated genes (Asb2, Gata3, Il13, Il1rl1, Il4, 
Il5 and Pparg) in the splenic CD4+ Th lymphocytes from 
the PBS-treated MRL/lpr mice compared with the PBS-
treated Balb/c control mice (Fig.  4a). However, follow-
ing LZ–SMS treatment, the mean values of the induced 
regulatory (iTreg) and natural Treg (nTreg) (Ccr6, Fosl1, 
Foxp3, Ikzf2, Il9, Irf4, Irf8, Myb, Nr4a1, Nr4a3, Pou2f2, 
Rel, Tgif1 and Tnfsf11) regulated gene expression lev-
els in the splenic CD4+ Th lymphocytes obtained from 
MRL/lpr mice were significantly higher than those of the 
Th17 cell-regulated genes (Il17a, Il17re, Il1r1, Il21, Rora 
and Rorc) in Th1 cells compared with the PBS treatment 
group (Fig. 4b). These results implied that LZ–SMS was 
exhibiting an immunoregulatory role towards the dif-
ferentiation of splenic CD4+ Th cells by inducing the 
differentiation of CD4+ Th cells into iTreg cells, whilst 
suppressing the differentiation of Th1 and Th17 cells 
in  vivo. Most of the Th cell differentiation-related tran-
scription factors, as well as the cytokine and receptor 
genes, were found to be up-regulated (ratio > 1.0) in the 
MRL/lpr mice belonging to the LZ–SMS treatment group 
compared with those in the PBS treatment group. This 
was especially true for the Treg differentiation-related 
genes IL-2 and Foxp3, which were up-regulated by more 
than 1.5-fold (Table 2).
Increase in the percentages of CD4+CD25+Foxp3+ Treg 
cells and IL‑10+ Breg cells in MRL/lpr mice following LZ–
SMS treatment
We found that the number of CD4+CD25+Foxp3+ 
Treg cells in the different groups of MRL/lpr mice 
decreased in a linear manner compared with the Balb/c 
control mice both with and without LZ–SMS treat-
ment (Fig.  5a–c). Compared with the PBS treatment 
group, the percentages of CD4+CD25+Foxp3+ Treg 
cells obtained from the splenic, thymic and peripheral 
blood cells in the severe SLE mice treated with LZ–SMS 
increased significantly (all P  <  0.05). Furthermore, the 
percentage of CD4+CD25+Foxp3+ Treg cells obtained 
from the splenic cells in the moderate SLE mice treated 
with LZ–SMS was significantly higher than the value 
achieved with PBS treatment (P = 0.004). Accordingly, 
the percentage ratios of the CD4+CD25+Foxp3+ Treg 
cells to the CD4+CD25– effector T cells obtained from 
the splenic, thymic and peripheral blood cells in the 
severe SLE mice treated with LZ–SMS, and from thymic 
and peripheral blood cells in moderate SLE mice with 
LZ–SMS treatment were significantly increased com-
pared with PBS treatment group (Fig.  5d, e). Finally, 
there was a significant increase in the percentage of 
IL-10+ Breg cells obtained from the thymic cells in mild 
SLE mice treated with LZ–SMS compared with the 
PBS-treated mice (Fig. 5g, P < 0.001).
Plasma concentrations of cytokines of MRL/lpr and Balb/c 
mice
There were decreases in the plasma concentrations of 
the inflammatory cytokines (IFN-γ, TNF-α and IL-6) 
observed in the moderate and severe SLE mice treated 
with LZ–SMS compared with the PBS-treated mice 
(Fig.  6). In particular, the plasma concentrations of the 
Th17 cytokines IL-21 and IL-17A in the severe SLE mice 
decreased significantly following their treatment with 
Fig. 3 Plasma concentrations of ANA and anti-ds-DNA antibody 
in LZ–SMS or PBS-treated MRL/lpr and Balb/c mice. Concentrations 
of plasma a ANA and b anti-ds-DNA are presented as bar charts 
showing the arithmetic mean plus SD. *P < 0.05, **P < 0.01, PBS- vs. 
LZ–SMS-treated MRL/lpr mice; &&P < 0.01, &&&P < 0.001, Balb/c control 
mice vs. PBS treated MRL/lpr mice; #P < 0.05, ##P < 0.01, ###P < 0.001, 
Balb/c control mice vs. LZ–SMS treated MRL/lpr mice (n = 5 in each 
group)
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the LZ–SMS material (Fig. 6c, f ). In contrast, the plasma 
concentration of IL-2 in the severe SLE mice (P = 0.004), 
as well as the concentrations of IL-12p70 in each group 
of MRL/lpr mice treated with LZ–SMS increased sig-
nificantly compared with those in the PBS-treated mice 
(Fig. 6b, d) (all P < 0.05). Furthermore, the plasma con-
centration of IL-10 in the severe SLE mice treated with 
LZ–SMS decreased significantly compared with that 
in the PBS-treated mice (Fig. 6f, P = 0.011). There were 
no significant differences in the plasma concentrations 
of IL-27 among the different groups of MRL/lpr mice 
treated with LZ–SMS compared with those in the PBS-
treated mice (Fig. 6e, P = 0.156), even though the plasma 
concentrations in the moderate and severe SLE mice 
were significantly lower than those of the Balb/c mice (all 
P < 0.01). However, the significant differences (P < 0.01) 
observed in the IL-27 concentration in this case may not 
be physiologically or immunologically relevant.
Discussion
In the present study, we have evaluated the anti-inflam-
matory efficacy of LZ–SMS following its oral and 
intraperitoneal administration in MRL/lpr mice. This 
LZ–SMS formulation can be suspended in PBS admin-
istered at a maximum concentration of 500  mg/kg/day 
[5]. MRL/lpr mice were orally administered this mate-
rial on a daily basis for 7  days, followed by intraperito-
neal administration for a further 7  days. Notably, none 
of the LZ–SMS components administered in this study 
exceeded the toxic doses reported in humans and mice 
[28, 31]. MRL/lpr mice treated with LZ–SMS showed a 
marked decrease in the extent of the symptoms associ-
ated with their SLE disease, including improvements in 
proteinuria, leukocyturia, interstitial nephritis and vessel 
infiltration. The eldest SLE mice (20–24  weeks) showed 
the most severe symptoms of lupus nephritis prior to 
treatment. Increases were also observed in the nephritis-
related clinical and biochemical indexes of the SLE mice, 
along with increases in age among the three different 
groups (mild, moderate and severe).
No data were obtained in the present study pertaining 
to the absorption or systemic distribution of the active 
ingredients of LZ–SMS. LZ contains β-glucan, which is 
an immunomodulating polysaccharide capable of poten-
tial interactions with pattern recognition receptors such 
as dectin-1. It is noteworthy that dectin-1 is a c-type lec-
tin, which can collaborate with TLR2 to trigger innate 
immune responses in antigen-presenting cells [32, 33], as 
well as inducing a balance between pro- and anti-inflam-
matory responses [34–37]. Furthermore, TLR2 signaling 
Fig. 4 RT2 profiler PCR array of mouse Th cell differentiation. The results of gene expressions of Th1 cells, Th2 cells, iTreg and nTreg, Th17 cells and 
“conventional Th vs. Treg cells” in a PBS-treated MRL/lpr vs. Balb/c mice (in ratio) and b LZ–SMS-treated vs. PBS-treated MRL/lpr mice (in ratio) are 
presented as box-and-whisker plots with the median (IQR). Mann–Whitney U test was used to assess the differences of mRNA expression among 
different genes of Th cells. *P < 0.05
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could potentially enhance the proliferation of Treg cells 
both in vitro and in vivo, which would result in the tran-
sient suppression of Foxp3 expression and the loss of 
their suppressive functions. It has been shown that the 
expression and function of dectin-1 are defective in the 
peripheral blood monocytes collected from patients with 
SLE and RA compared with healthy controls, suggest-
ing that dectin-1 could be involved in the pathogenesis 
of autoimmune inflammatory conditions [38]. Dectin-1 
signaling could also make a significant contribution to 
the expansion of Treg cells and play a critical role in the 
prevention of several inflammatory conditions, such as 
type 1 diabetes [39]. The protocol used for the intraperi-
toneal administration of this combination therapy was 
the same as that used for its oral administration, except 
that the dosage used in the former of these two cases was 
reduced to 50 mg/kg/day because of the limited solubility 
of LZ–SMS.
The pronounced reduction observed in the nephri-
tis symptoms of the mice in the present study following 
their treatment with LZ–SMS could be attributed to the 
ability of LZ–SMS to down-regulate the expression of 
multiple inflammatory-related genes (e.g., Th17), and 
Th1-cell regulated genes, as well as genes associated with 
the expression of inflammatory cytokines and receptors, 
chemokines, adhesion molecules and chronic inflam-
mation-activated proteins [40]. These responses could 
also be related to the ability of LZ–SMS to up-regulate 
the expression of regulatory iTreg-related genes and 
their downstream transcription factors, such as Foxp3, 
Stat1 and Stat4. Although the mechanism of action for 
the anti-nephritic efficacy of this LZ–SMS formulation 
remains unclear, Lingzhi has been reported to regulate 
the production of several pro-inflammatory cytokines 
associated with the pathogenesis of SLE in peripheral 
mononuclear cells [5, 15–17].
The LZ–SMS formulation used in the present study led 
to an increase in the percentages of immunomodulatory 
CD4+CD25+Foxp3+ Treg cells and IL-10+ Breg cells in 
the SLE mice compared with those in the PBS-treated 
SLE mice. These elevated levels of Treg cells could sub-
sequently lead to (1) an increase in the frequency ratio 
of Treg to Teff cells; (2) an increase in the plasma con-
centration of IL-2, which could lead to an increase in the 
differentiation of Treg cells from naive T cells, the devel-
opment of Treg cells in the thymus and the immunoregu-
latory roles of the Treg cells [41, 42]; or (3) considerable 
reductions in the amounts of several proinflammatory 
cytokines, including IL-21, TNF-α, IL-6 and IL-17A. 
Although the frequency and phenotypic characteristics 
of the Treg cells in the MRL/lpr mice were similar to 
those found in the normal mice, the inhibitory functions 
of the Treg cells in the MRL/lpr mice could be impaired 
by the LZ–SMS treatment [43]. Further functional assays 
are therefore required to develop a better understand-
ing of the roles played by TLR2 and dectin-1 in Treg 
cells during the treatment of SLE in MRL/lpr mice with 
LZ–SMS. The overall results showed decreases in the 
plasma concentrations of ANA and anti-dsDNA anti-
body in the LZ–SMS-treated SLE mice (Fig. 3), indicat-
ing that the suppressive activity of LZ–SMS would be 
Table 2 Th differentiation PCR array analysis
cDNA samples were obtained from splenic cells of 24 weeks old female MRL/lpr 
mice 1 day after treatment. Values represent fold increase of LZ–SMS treatment 
(500 mg/kg/day of LZ–SMS formulation in 400 μL PBS for day 1–7 by oral 
administration followed by 50 mg/kg/day of soluble LZ–SMS in 400 μL PBS for 
day 8–14 by intraperitoneal route) versus the PBS treatment group
Transcription Factors Cytokines and receptors
Gene LZ–SMS PBS Gene LZ–SMS PBS
Fosl1 1.94 Tnf 0.98
Nr4a1 5.12 Il1r2 1.94
Nr4a3 6.46 Il17re 1.10
Hoxa10 1.06 Il21 2.01
Rel 3.22 Ccr6 1.11
Irf4 2.03 Csf2 0.79
Nfatc1 1.88 Il4 1.12
Irf8 1.57 Il18r1 1.78
Id2 1.74 Ccr3 3.61
Gata4 1.99 Ccl5 0.96
Rora 5.04 Il13ra1 0.69
Cebpb 1.72 Il1rl1 0.82
Stat1 1.58 Il18 0.84
Zbtb7b 0.83 Il2ra 0.35
Pou2f2 1.40 Ccl7 0.73
Maf 2.14 Il18rap 2.27
Stat6 0.97 Ccr4 1.34
Rorc 1.19 Il12p40 0.53
Runx1 1.29 Il1r1 3.90
Gata3 1.68 Il2 2.63
Zeb1 1.03 Ccl11 1.38
Nfatc2 2.01 Il12rb2 2.68
Foxp3 1.91 Il4ra 1.99
Nfatc2ip 1.53 Il9 6.13
Runx3 2.00 Il13 1.99
Hoxa3 1.22
Stat4 1.41
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not only limited to CD4+ Treg cells, but also related to 
the propagation of IL-10+ Breg cells. However, the low 
frequency of IL-10+ Breg cells in peripheral blood cells, 
and the reduced plasma concentration of IL-10 in the 
LZ–SMS-treated severe SLE mice could limit the immu-
noregulatory role of LZ–SMS in this context because of 
the exacerbation of the SLE disease.
Conclusion
Upon LZ–SMS treatment, the percentages of 
CD4+CD25+Foxp3+ Treg and IL-10+ Breg cells increased 
significantly in the SLE mice compared with those in 
the untreated mice. Furthermore, there was a decrease 
in the plasma concentrations of specific inflammatory 
cytokines, as well as a down-regulation in the expression 
Fig. 5 Characterization of CD4+CD25+Foxp3+ Tregs and IL-10 + Bregs in LZ–SMS or PBS-treated MRL/lpr and Balb/c mice. Bar charts show the 
arithmetic mean plus SD of the percentages of CD4+CD25+Foxp3+ Tregs in a splenic, b thymic and c peripheral blood cells; and the ratios of 
CD4+CD25+Foxp3+ Treg %/CD4+CD25− effector T cell % in d splenic, e thymic and f peripheral blood cells; and the percentages of IL-10 + Breg 
cells in g splenic, h thymic and i peripheral blood cells. *P < 0.05, **P < 0.01, ***P < 0.001, LZ–SMS vs. PBS treatment; &P < 0.05, &&P < 0.01, 
&&&P < 0.001, Balb/c control mice vs. PBS-treated MRL/lpr mice; #P < 0.05, ##P < 0.01, ###P < 0.001, Balb/c control mice vs. LZ–SMS-treated MRL/lpr 
mice (n = 5 in each group)
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of the corresponding cytokine-related genes in the LZ–
SMS-treated mice. The clinical characteristics of the LZ–
SMS-treated SLE mice were also improved significantly.
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